

ANNOUNCEMENT NO. 208

30 July 2021

Clarification of expectations for revenue and operating profit for 2020/21

ChemoMetec clarifies the expectations for revenue and operating profit for the financial year 2020/21, which covers the period 1 July 2020 to 30 June 2021.

Based on the preliminary financial figures, ChemoMetec now expects a revenue of around DKK 281 million in 2020/21, against previously announced DKK 275-278 million. Furthermore, an operating profit (EBITDA) of around DKK 135 million is expected, against previously announced DKK 130-133 million.

ChemoMetec expects to release its 2020/21 Annual Report on Thursday, 16 September 2021.

For further information, please contact

Steen Søndergaard, CEO, ChemoMetec A/S

Tel.: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com.